NCT01846468View on ClinicalTrials.gov

An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction

PHASE1CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

March 1, 2013

Primary Completion Date

June 28, 2014

Study Completion Date

June 28, 2014

Conditions
Chronic Renal Insufficiency
Interventions
DRUG

LHW090

1 mg, 12.5 mg, 100 mg capsules

DRUG

Placebo

Matching placebo capsules

Trial Locations (2)

32809

Novartis Investigative Site, Orlando

37920

Novartis Investigative Site, Knoxville

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY